Key Highlights
- Eli Lilly’s experimental obesity medication retatrutide delivered up to 70.3 pounds of weight reduction (28.3% of total body weight) across an 80-week Phase 3 clinical study.
- The data suggests superior performance compared to Lilly’s existing weight-loss therapies Zepbound and Foundayo when examined across separate clinical studies.
- Approximately 45% of 2,500 study participants reached 30% or greater weight reduction — a benchmark historically only achieved through surgical weight-loss procedures.
- The 4mg dosing option demonstrated excellent tolerability, recording fewer treatment discontinuations than the placebo cohort.
- LLY shares increased approximately 1% Thursday morning; the stock remains down roughly 5% for the current year.
Eli Lilly’s upcoming obesity treatment has generated some of the most remarkable clinical data witnessed in the field of weight management.
Retatrutide, administered as a once-weekly injection that activates three distinct gut hormones, successfully completed a pivotal late-stage clinical study Thursday. Participants living with obesity who received the maximum 12mg dosage achieved an average body weight reduction of 28.3% — approximately 70.3 pounds — throughout the 80-week treatment period. Study participants receiving the 9mg dosage experienced an average weight decrease of 64.4 pounds.
Meanwhile, the control group receiving placebo showed only a 2.2% reduction in body weight.
LLY stock climbed approximately 1% during Thursday’s morning session. Year-to-date, shares remain down roughly 5.2% amid growing competition within the GLP-1 therapeutic market.
Nearly 45% of the approximately 2,500 study participants achieved 30% or greater total weight reduction. This milestone has traditionally been attainable only through surgical bariatric procedures.
Dan Skovronsky, Lilly’s chief scientific and product officer, told CNBC that 30% weight loss is “an incredible number to see” with this class of medicine.
Retatrutide Performance Versus Current Treatments
Retatrutide employs a distinct mechanism from Lilly’s existing product portfolio. The medication activates receptor sites for three separate hormones — GLP-1, GIP, and glucagon — versus two for Zepbound and a single hormone for earlier-generation GLP-1 medications.
Although head-to-head comparisons between separate clinical trials present challenges, the results are striking. Zepbound’s maximum dosage achieved approximately 20–22% weight reduction in its registration trial. Foundayo, Lilly’s oral GLP-1 tablet, demonstrated more modest outcomes.
A newly tested 4mg dosage option in this study caught analysts off guard. It delivered 19% weight reduction — comparable to high-dose Zepbound — while exhibiting superior tolerability characteristics. Only 4% of participants receiving this dosage discontinued therapy due to adverse reactions, compared to nearly 5% among placebo recipients.
The medication’s safety characteristics aligned broadly with other GLP-1 class therapies. Digestive system-related adverse effects including nausea (42% at maximum dosage) and diarrhea (32%) represented the most frequently reported issues. No cardiovascular or hepatic complications emerged, which some market observers had identified as potential concerns given the medication’s glucagon mechanism.
Lilly reported a modestly elevated incidence of urinary tract infections compared to placebo, though most cases were mild in severity. Skovronsky indicated the UTIs might correlate with the rapidity and magnitude of weight reduction, noting comparable patterns observed following bariatric surgical procedures.
Regulatory Path Forward for Retatrutide
This marks the third successful late-stage outcome for retatrutide. The compound previously demonstrated positive results in a diabetes-focused trial earlier this year and cleared a smaller investigation involving patients with obesity and knee osteoarthritis in December 2025.
TD Cowen market analysts project the medication could deliver $3.8 billion in annual revenue by 2030, contingent upon regulatory clearance.
Lilly commands approximately 60% of the GLP-1 therapeutic market, according to company data. Novo Nordisk’s Wegovy pill has captured market share in the oral weight-loss category, where Lilly’s Foundayo also competes.
Lilly announced intentions to leverage these clinical findings to advance toward a regulatory submission for retatrutide.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
